T-DM1 functions through multiple mechanisms of action, including the selective delivery of DM1 to the HER2+ tumor cell, trastuzumab-mediated suppression of the HER2 signaling pathway, inhibition of HER2 extracellular domain shedding, and induction of antibody-dependent cell-mediated cytotoxicity (ADCC) [59]. This evidence concerns the gene ERBB2 and neoplasm.